Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Following product approval, further confirmation of the MR Conditional Tachyarrhythmia Therapy Systems sensing and detection performance post MRI exposure will be obtained by actively monitoring de-identified device data obtained through the Medtronic CareLink® Network.
Pre-clinical testing and clinical data has demonstrated the safety and effectiveness of magnetic resonance (MR) Conditional Tachyarrhythmia Therapy Systems in the MR environment when used according to labeling requirements. Following approval, further confirmation of the MR Conditional Tachyarrhythmia Therapy Systems sensing and detection performance post MRI exposure will be obtained by actively monitoring de-identified device data obtained through the Medtronic CareLink® Network. MR conditional tachyarrhythmia therapy system enrolled in the Medtronic CareLink® Network (CL) will be used to prospectively assess spontaneous Ventricular Fibrillation (VF) episode detection following MRI exposure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients implanted with an MR-conditional Tachy device system | Patients implanted with an MR-conditional Tachy device system in the routine care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Implant of an MR-conditional Tachy device system | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of episodes with ≥ 5 seconds VF detection delay in the MR conditional tachyarrhythmia therapy system following MRI exposure. | The primary objective will be analyzed and reported when 50 patients with a true VF episode following MR exposure have been identified | up to 5 years post-approval. |
| Measure | Description | Time Frame |
|---|---|---|
| The number of patients with 2 or more scans | The estimate of patients receiving multiple MRI scans will include all patients regardless if the patient has experienced a VF episode. | up to 5 years post-approval |
| Pre-MRI and post-MRI LV lead PCT measurements obtained through CareLink |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
MR conditional tachyarrhythmia therapy system enrolled in the Medtronic CareLink® Network (CL) will be used to prospectively assess spontaneous Ventricular Fibrillation (VF) episode detection following MRI exposure.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Product Surveillance Registry Medtronic Product Surveillance Registry | Medtronic | Study Chair |
Not provided
Not provided
| ID | Term |
|---|---|
| D013610 | Tachycardia |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D000075224 | Cardiac Conduction System Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Pre-MRI and post-MRI LV lead PCT measurements obtained through CareLink will be summarized for MR CRT-D patients. Summary statistics will be presented separately for pre-MRI and post-MRI PCT measurements |
| up to 5 years post-approval |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |